MYDECINE
Revolutionizing Natures Medicine for Mental Health & Vitality
Mydecine Innovations Group Logo 2021
Revolutionizing Nature's Medicine
for Mental Health & Vitality

About Us


Mydecine Innovations Group™️ (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that Psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. 

Team leadership is key, The Scientific Advisory Board (“SAB”) that Mydecine has pulled together from its operational branches is enviable in the field of mental health solutions. Its current members are world-renowned medical and scientific professionals drawn from within academic, research and development, military, and corporate environments. As leaders in the field of PTSD, Mental Health including clinical practice, and advocacy, each member has made significant contributions to advancing the field and are committed to furthering Mydecine’s mission. The mandate of this SAB continues to provide strategic guidance and direction for Mydecine’s clinical trials for PTSD, underpinned by pure data research, therapy, and scientific programs, advise on intellectual property; and, contribute commentary on Mydecine’s telehealth platform, Mindleap Health™.  

Mydecine has also successfully completed multiple acquisitions since its inception.
View Acquisitions

Our Portfolio

Natural Health Products
Learn More→
We are discovering, extracting, and combining powerful fungtional© and psychedelic ingredients in mushrooms to balance and enhance the brain.
Research & Development
We are charting new paths with Neurological Disorder Medicines based on the novel compounds found in psychedelic medicines.
Learn More→
Learn More→Digital Health Solutions
We are developing breakthrough digital technologies to augment mental healthcare with data, digital therapeutics, and global connectivity.

Our Story

We started Mydecine Innovations Group™️ with the goal of revolutionizing the way people live and experience life by offering cutting edge natural products and technologies. Our international team has been described as a collection of passionate business leaders, scientists, mental health professionals and technology visionaries.

We are inspired by the future, the innovators, the dreamers; and our products embody this  spirit. They are built for those that aspire to be healthy physically and spiritually while living life to the fullest and daring to disrupt the norm.

Our passion sent us on a mission to develop high quality products and disruptive new technologies so we can contribute to making the world a better place.

For Investors

Ticker Symbols
NEO: MYCO
OTC: MYCOF
FSE: 0NFA
SEDAR ProfileInvestor Presentation
1d
5d
1m
6m
ytd
1y

Mydecine Full Year 2020 Financial Results Conference Call

Monday, May 3, 2021 10:30 a.m. ET

Live Call: 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International)
Webcast: http://public.viavid.com/index.php?id=144246

For interested individuals unable to join the conference call, a replay of the call will be available through May 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13718466. The online archive of the webcast will be available here after the conclusion of the call.

See All News →

Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th

May 10, 2021
Mydecine CEO Josh Bartch will speak on the panel titled Investing in the Mental Health Crisis Through Psychedelics.
Read More →

Mydecine CSO Rob Roscow Joins The Dales Report Podcast

May 6, 2021
Roscow talks Mydecine’s upcoming phase 2a clinical trials on psylocibin-assisted PTSD treatments, barriers presented by COVID, and the new novel drug candidates.
Read More →

Mydecine Announces Partnership with LeadGen Labs

May 5, 2021
LeadGen Labs partnership will considerably increase Mydecine’s synthesis capabilities of novel molecules.
Read More →
News & Media
Text Link